$10.73
0.393.77%
Dern. MÀJ: Oct 15, 7:14 PM
$10.66
0.323.1%
ADMA Biologics (ADMA) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
fiscal year (2026) a publié ses dernières prévisions le $530M - $560M pour ADMA Biologics {{epsDirection}}. La société a prévu un chiffre d'affaires compris entre {{epsPriorRange}} et {{revenueDirection}} pour la période.
Par rapport aux prévisions précédentes, {{newestDate}} {{directionSummary}} ses prévisions de chiffre d'affaires ont été revues à la baisse, passant d'une fourchette précédente de undefined à undefined.
undefined a publié undefined mises à jour de ses recommandations entre undefined et undefined. undefined
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.17 | $0.20 | $0.20 | $0.16 |
| Actual | $0.16 | $0.17 | $0.21 | $0.16 |
| Surprise | -5.88% | -15.0% | +7.50% | 0.00% |
| Revenue | ||||
| Estimate | $126.1M | $140.0M | $139.8M | $130.4M |
| Actual | $124.4M | $114.5M | $139.2M | $134.2M |
| Surprise | -1.34% | -18.2% | -0.46% | +2.96% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.20 | $0.24 | $0.17 | $0.20 |
| Revenue | ||||
| Consensus | $138.5M | $157.1M | — | — |
| Trimestre Fiscal | Date de Déclaration | BPA Réel | BPA Estimé | Surprendre % |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $0.16 | $0.17 | -5.88 % |
| Q1 | May 6, 2026 | $0.17 | $0.20 | -15.0 % |
| Q4 | Feb 25, 2026 | $0.22 | $0.20 | 7.50 % |
| Q3 | Nov 5, 2025 | $0.16 | $0.16 | 0.00 % |
| Trimestre Fiscal | Date de Déclaration | Revenu Réel | Revenu Estimé | Surprendre % |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $124.40M | $126.08M | -1.34 % |
| Q1 | May 6, 2026 | $114.49M | $139.97M | -18.2 % |
| Q4 | Feb 25, 2026 | $139.16M | $139.80M | -0.46 % |
| Q3 | Nov 5, 2025 | $134.22M | $130.36M | 2.96 % |